
SenzaGen Q1 - Solid sales and EBITDA break even

Redeye provides an update following SenzaGen's Q1 report. Sales during the quarter aligned with our expectations; however, we highlight the quarterly EBITDA and argue that SenzaGen is one step closer to profitability. We only make some minor estimate changes and our fair value range remains intact.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[SenzaGen Q1 - Solid sales and EBITDA break even](#)